Nuvation Bio Director Buys 25K Shares After Nuvalent Deal Spurs Optimism

Nuvation Bio shares gained fresh support after Director Robert Mashal purchased 25,000 shares on June 9 at $4.73. The insider transaction follows GSK’s $10.6 billion acquisition of rival Nuvalent, which analysts say underscores strategic value in the ROS1 lung-cancer space and lifts Nuvation Bio’s own Ibtrozi prospects. RBC Capital reiterated its Buy rating with a $20 target, citing Q1 revenue of $83.2 million that beat estimates and 18% growth in Ibtrozi sales to $18.5 million.